Your browser doesn't support javascript.
loading
Herbal Medicines for the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Iyengar, Preetha; Godoy-Brewer, Gala; Maniyar, Isha; White, Jacob; Maas, Laura; Parian, Alyssa M; Limketkai, Berkeley.
Affiliation
  • Iyengar P; Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA.
  • Godoy-Brewer G; Department of Medicine, University of Miami, Miami, FL 33136, USA.
  • Maniyar I; Center for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA.
  • White J; Welch Library, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Maas L; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Parian AM; Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Limketkai B; Center for Inflammatory Bowel Diseases, Vatche and Tamar Manoukian Division of Digestive Diseases, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA.
Nutrients ; 16(7)2024 Mar 23.
Article in En | MEDLINE | ID: mdl-38612967
ABSTRACT
Herbal medicines are used by patients with IBD despite limited evidence. We present a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating treatment with herbal medicines in active ulcerative colitis (UC). A search query designed by a library informationist was used to identify potential articles for inclusion. Articles were screened and data were extracted by at least two investigators. Outcomes of interest included clinical response, clinical remission, endoscopic response, endoscopic remission, and safety. We identified 28 RCTs for 18 herbs. In pooled analyses, when compared with placebo, clinical response rates were significantly higher for Indigo naturalis (IN) (RR 3.70, 95% CI 1.97-6.95), but not for Curcuma longa (CL) (RR 1.60, 95% CI 0.99-2.58) or Andrographis paniculata (AP) (RR 0.95, 95% CI 0.71-1.26). There was a significantly higher rate of clinical remission for CL (RR 2.58, 95% CI 1.18-5.63), but not for AP (RR 1.31, 95% CI 0.86-2.01). Higher rates of endoscopic response (RR 1.56, 95% CI 1.08-2.26) and remission (RR 19.37, 95% CI 2.71-138.42) were significant for CL. CL has evidence supporting its use as an adjuvant therapy in active UC. Research with larger scale and well-designed RCTs, manufacturing regulations, and education are needed.
Key words

Full text: 1 Database: MEDLINE Language: En Journal: Nutrients Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Language: En Journal: Nutrients Year: 2024 Type: Article Affiliation country: United States